Mellowmood77 Monday, 09/16/19 01:07:35 PM Re: sts66 post# 214598 Post # of 220285 STS, this is GREAT news for Amarin. BAD news for most other drugs. Amarin currently sets at $18K/QALY. 16k if you include revascularizations. This means for AMARIN to reach the 100k/QALY threshold you referenced it would have to be priced 5.5x higher. So AMARIN or buyer could TRIPLE the price of Vascepa and still be considered cost effective. In comparison, REPATHA sits at $315,000/ QALY for all eligible patients and for it to reach the $100k/QALY threshold they would have to CUT its price by 80% to $2,306 annually. I believe people have really underestimated how positive of a report ICER was for Vascepa. It really is one of the cheapest clinically effective (non generic) drugs of the modern era. Politicians should be praising Amarin for keeping the cost so low and this is why I implore everyone to contact their state senators and representatives and let them know about Amarin and their game changer drug Vascepa.